Casdin Partners GP, LLC's Form 4 filing
Maxcyte, Inc. (MXCT) · filed Jul 6, 2022
- Accession no.
- 0000919574-22-004059
- Filed
- Jul 6, 2022, 5:01 PM ET
- Trade date
- Jul 1, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $13.9M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Casdin Partners GP, LLCCIK 0001534260 | 10% Owner |
| Casdin Capital, LLCCIK 0001534261 | 10% Owner |
| Casdin EliCIK 0001534264 | 10% Owner |
| Casdin Partners Master Fund, L.P.CIK 0001534265 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock, par value $0.01 per share | SSaleDisposed | −3,235,548 | $4.30 | −$13,912,856.4 | 10,735,786 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.